Updated insights into predictive biomarkers for response to cardiac resynchronization therapy - A literature review

1 Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Search in Google Scholar

Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA). Eur Heart J. 2021 Sep 14;42(35):3427-520. DOI: 10.1093/eurheartj/ehab699 Search in Google Scholar

2 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726. DOI: 10.1093/eurheartj/ehab368 Search in Google Scholar

3 Nakai T, Ikeya Y, Kogawa R, Okumura Y. Cardiac resynchronization therapy: Current status and near-future prospects. J Cardiol. 2022 Mar 1;79(3):352-7. DOI: 10.1016/j.jjcc.2021.10.021 Search in Google Scholar

4 Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G, et al. NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem. 2013;13(2):82-94. DOI: 10.2174/1568026611313020002 Search in Google Scholar

5 Bakos Z, Chatterjee NC, Reitan C, Singh JP, Borgquist R. Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score. BMC Cardiovasc Disord. 2018 Apr 24;18(1):70. DOI: 10.1186/s12872-018-0802-8 Search in Google Scholar

6 Davoodi G, Bagheri A, Yamini-Sharif A, Boroumand M, Saroukhani S, Sahebjam M. Evaluation of in-hospital NT-proBNP changes in heart failure patients to identify the six-month clinical response following cardiac resynchronization therapy. Acta Med Iran. 2014;52(1):15-23. Search in Google Scholar

7 Shalaby AA, Abraham WT, Fonarow GC, Bersohn MM, Gorcsan J, Lee LY, et al. Association of BNP and Troponin Levels with Outcome among Cardiac Resynchronization Therapy Recipients. Pacing Clin Electrophysiol PACE. 2015 May;38(5):581-90. DOI: 10.1111/pace.12610 Search in Google Scholar

8 Truong QA, Szymonifka J, Januzzi JL, Contractor JH, Deaño RC, Chatterjee NA, et al. Cardiorenal Status using Amino Terminal Pro Brain Natriuretic Peptide and Cystatin C on Cardiac Resynchronization Therapy Outcomes: From the BIOCRT Study. Heart Rhythm. 2019 Jun;16(6):928-35. DOI: 10.1016/j. hrthm.2018.12.023 Search in Google Scholar

9 Kosztin A, Széplaki G, Kovács A, Földes G, Szokodi I, Vivien Nagy K, et al. Impact of CT-apelin and NT-proBNP on identifying nonresponders to cardiac resynchronization therapy. Biomark Biochem Indic Expo Response Susceptibility Chem. 2017;22(3-4):279-86. DOI: 10.1080/1354750X.2016.1217931 Search in Google Scholar

10 Yokoyama Y, Kataoka N, Nakai M, Matsuo A, Fujiwara A, Wakamiya A, et al. A new biomarker of cardiac resynchronization therapy response: cGMP to mature BNP ratio. J Cardiol. 2022 Jun;79(6):727-33. DOI: 10.1016/j.jjcc.2021.12.015 Search in Google Scholar

11 Hoogslag GE, Höke U, Thijssen J, Auger D, Marsan NA, Wolterbeek R, et al. Clinical, echocardiographic, and neurohormonal response to cardiac resynchronization therapy: are they interchangeable? Pacing Clin Electrophysiol PACE. 2013 Nov;36(11):1391-401. DOI: 10.1111/pace.12214 Search in Google Scholar

12 Almeida-Morais L, Abreu A, Oliveira M, Silva Cunha P, Rodrigues I, Portugal G, et al. Impact of cardiac resynchronization therapy on inflammatory biomarkers and cardiac remodeling: The paradox of functional and echocardiographic response. Rev Port Cardiol. 2018 Feb;37(2):105-13. DOI: 10.1016/j.repc.2017.06.017 Search in Google Scholar

13 Kerekanič M, Hudák M, Mišíková S, Komanová E, Bohó A, Kyselovič J, et al. The prognostic value of high sensitive cardiac troponin I in patients receiving cardiac resynchronisation therapy. Acta Cardiol. 2018 Apr;73(2):141-6. DOI: 10.1080/00015385.2017.1351248 Search in Google Scholar

14 Nauffal V, Tanawuttiwat T, Zhang Y, Rickard J, Marine JE, Butcher B, et al. Predictors of mortality, LVAD implant, or heart transplant in primary prevention cardiac resynchronization therapy recipients: The HF-CRT score. Heart Rhythm. 2015 Dec;12(12):2387-94. DOI: 10.1016/j.hrthm.2015.07.026 Search in Google Scholar

15 Liu T, Song D, Dong J, Zhu P, Liu J, Liu W, et al. Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure. Front Physiol. 2017 Apr 24;8:238. DOI: 10.3389/fphys.2017.00238 Search in Google Scholar

16 Zaborska B, Pilichowska-Paszkiet E, Makowska E, Sygitowicz G, Słomski T, Zaborski M, et al. Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy. Sci Rep. 2021 Nov 1;11(1):21390. DOI: 10.1038/s41598-021-00984-2 Search in Google Scholar

17 Beaudoin J, Singh JP, Szymonifka J, Zhou Q, Levine RA, Januzzi JL, et al. Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study. Can J Cardiol. 2016 Dec;32(12):1478-84. DOI: 10.1016/j.cjca.2016.05.013 Search in Google Scholar

18 Andre C, Piver E, Perault R, Bisson A, Pucheux J, Vermes E, et al. Galectin-3 predicts response and outcomes after cardiac resynchronization therapy. J Transl Med. 2018 Nov 3;16:299. DOI: 10.1186/s12967-018-1675-4 Search in Google Scholar

19 Truong QA, Januzzi JL, Szymonifka J, Thai W ee, Wai B, Lavender Z, et al. Coronary Sinus Biomarker Sampling Compared to Peripheral Venous Blood for Predicting Outcomes In Patients with Severe Heart Failure Undergoing Cardiac Resynchronization Therapy: The BIOCRT Study. Heart Rhythm Off J Heart Rhythm Soc. 2014 Dec;11(12):2167-75. DOI: 10.1016/j.hrthm.2014.07.007 Search in Google Scholar

20 Stolen CM, Adourian A, Meyer TE, Stein KM, Solomon SD. Plasma Galectin-3 and Heart Failure Outcomes in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). J Card Fail. 2014 Nov 1;20(11):793-9. DOI: 10.1016/j.cardfail.2014.07.018 Search in Google Scholar

21 Sokal A, Lenarczyk R, Kowalski O, Mitrega K, Pluta S, Stabryla-Deska J, et al. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population. Heart Rhythm. 2016 May;13(5):1088-95. DOI: 10.1016/j.hrthm.2015.12.036 Search in Google Scholar

22 Massoullié G, Sapin V, Ploux S, Rossignol P, Mulliez A, Jean F, et al. Low fibrosis biomarker levels predict cardiac resynchronization therapy response. Sci Rep. 2019 Apr 15;9(1):6103. DOI: 10.1038/s41598-019-42468-4 Search in Google Scholar

23 Sunman H, Canpolat U, Yorgun H, Özkan A, Yalçın MU, Bayrak T, et l. Association between reverse electrical remodeling and cardiac fibrosis markers in patients with cardiac resynchronization therapy. Turk Kardiyol Dernegi Arsivi Turk Kardiyol Derneginin Yayin Organidir. 2018 Mar;46(2):84-91. DOI: 10.5543/tkda.2017.80236 Search in Google Scholar

24 Beltrami M, Galluzzo A, Brocci RT, Paoletti Perini A, Pieragnoli P, Garofalo M, et al. The role of fibrosis, inflammation, and congestion biomarkers for outcome prediction in candidates to cardiac resynchronization therapy: is “response” the right answer? Front Cardiovasc Med. 2023 Jun 12;10:1180960. DOI: 10.3389/fcvm.2023.1180960 Search in Google Scholar

25 Spinale FG, Meyer TE, Stolen CM, Van Eyk JE, Gold MR, Mittal S, et al. Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 May;16(5):743-53. DOI: 10.1016/j. hrthm.2018.11.026 Search in Google Scholar

26 Ptaszynska-Kopczynska K, Sawicka E, Marcinkiewicz-Siemion M, Tarasiuk E, Lisowska A, Szpakowicz A, et al. Chemokines profile in patients with chronic heart failure treated with cardiac resynchronization therapy. Adv Med Sci. 2020 Mar;65(1):102-10. DOI: 10.1016/j.advms.2019.11.007 Search in Google Scholar

27 Széplaki G, Boros AM, Szilágyi S, Osztheimer I, Jenei Z, Kosztin A, et al. Complement C3a predicts outcome in cardiac resynchronization therapy of heart failure. Inflamm Res Off J Eur Histamine Res Soc Al. 2016 Dec;65(12):933-40. DOI: 10.1007/s00011-016-0976-4 Search in Google Scholar

28 Pujol C, Varo Cenarruzabeitia N, Rodríguez Mañero M, Barba J, Castaño Rodríguez S, Macías Gallego A, et al. Role of sCD40L in the prediction of super-response to cardiac resynchronization therapy. An Sist Sanit Navar. 2021 Aug 20;44(2):205-14. DOI: 10.23938/ASSN.0947 Search in Google Scholar

29 Belperio J, Horwich T, Abraham WT, Fonarow GC, Gorcsan J, Bersohn MM, et al. Inflammatory Mediators and Clinical Outcome in Patients With Advanced Heart Failure Receiving Cardiac Resynchronization Therapy. Am J Cardiol. 2016 Feb 15;117(4):617-25. DOI: 10.1016/j.amjcard.2015.11.049 Search in Google Scholar

30 Brouwers C, Versteeg H, Meine M, Heijnen CJ, Kavelaars AM, Pedersen SS, et al. Association between brain natriuretic peptide, markers of inflammation and the objective and subjective response to cardiac resynchronization therapy. Brain Behav Immun. 2014 Aug;40:211-8. DOI: 10.1016/j.bbi.2014.03.017 Search in Google Scholar

31 Perge P, Boros AM, Szilágyi S, Zima E, Molnár L, Gellér L, et al. Novel Biomarkers in Cardiac Resynchronization Therapy: Hepatocyte Growth Factor Is an Independent Predictor of Clinical Outcome. Rev Espanola Cardiol Engl Ed. 2019 Jan;72(1):48-55. DOI: 10.1016/j.rec.2017.12.015 Search in Google Scholar

32 Ajaero CN, Chong CR, Procter NEK, Liu S, Chirkov YY, Heresztyn T, et al. Does cardiac resynchronization therapy restore peripheral circulatory homeostasis? ESC Heart Fail. 2018 Feb;5(1):129-38. DOI: 10.1002/ehf2.12211 Search in Google Scholar

33 Martins S, Carvalheiro T, Laranjeira P, Martinho A, Elvas L, Gonçalves L, et al. Impact of cardiac resynchronization therapy on circulating IL-17 producing cells in patients with advanced heart failure. J Interv Card Electrophysiol Int J Arrhythm Pacing. 2019 Apr;54(3):257-65. DOI: 10.1007/s10840-018-0491-3 Search in Google Scholar

34 Sunman H, Özkan A, Yorgun H, Canpolat U, Karabulut E, Bayrak T, et al. Evaluating the effects of cardiac resynchronization therapy on pathophysiological pathways of heart failure using surrogate biomarkers. Cardiol J. 2018 Feb 27;25(1):42-51. DOI: 10.5603/CJ.a2017.0111 Search in Google Scholar

35 Sultan A, Wörmann J, Lüker J, V D Bruck JH, Plenge T, Rudolph V, et al. Significance of myeloperoxidase plasma levels as a predictor for cardiac resynchronization therapy response. Clin Res Cardiol Off J Ger Card Soc. 2021 Aug;110(8):1173-80. DOI: 10.1007/s00392-020-01690-1 Search in Google Scholar

36 Önal U, Valenzuela-Sánchez F, Vandana KE, Rello J. Mid-Regional Pro-Adrenomedullin (MR-proADM) as a Biomarker for Sepsis and Septic Shock: Narrative Review. Healthcare. 2018 Sep 3;6(3):110. DOI: 10.3390/healthcare6030110 Search in Google Scholar

37 Arrigo M, Truong QA, Szymonifka J, Rivas-Lasarte M, Tolppanen H, Sadoune M, et al. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. Europace. 2017 Nov;19(11):1848-54. DOI: 10.1093/europace/euw305 Search in Google Scholar

38 Feng Z, Akinrimisi OP, Gornbein JA, Truong QA, Das S, Singh JP, et al. Combination Biomarkers for Risk Stratification in Patients With Chronic Heart Failure Biomarkers Prognostication in HF. J Card Fail. 2021 Dec;27(12):1321-7. DOI: 10.1016/j.cardfail.2021.05.028 Search in Google Scholar

39 Sunman H. Vitamin D Levels Predict the Response to Cardiac Resynchronization Therapy in Patients with Systolic Heart Failure. Turk Kardiyol Dernegi Arsivi-Arch Turk Soc Cardiol [Internet]. 2016 [cited 2023 Aug 21]; Available from: https://archivestsc.com/jvi. aspx?un=TKDA-28848 DOI: 10.5543/tkda.2016.28848 Search in Google Scholar

40 Perge P, Boros AM, Gellér L, Osztheimer I, Szilágyi S, Tahin T, et al. Vitamin D Deficiency Predicts Poor Clinical Outcomes in Heart Failure Patients Undergoing Cardiac Resynchronization Therapy. Dis Markers. 2019 Oct 13;2019:4145821. DOI: 10.1155/2019/4145821 Search in Google Scholar

41 Ajijola OA, Chatterjee NA, Gonzales MJ, Gornbein J, Liu K, Li D, et al. Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure. JAMA Cardiol. 2020 Mar;5(3):318-25. DOI: 10.1001/jamacardio.2019.4717 Search in Google Scholar

42 Yang S, Liu Z, Liu S, Ding L, Chen K, Hua W, et al. Association of baseline big endothelin-1 level with long-term prognosis among cardiac resynchronization therapy recipients. Clin Biochem. 2018 Sep;59:25-30. DOI: 10.1016/j.clinbiochem.2018.06.006 Search in Google Scholar

43 Boros AM, Széplaki G, Perge P, Jenei Z, Bagyura Z, Zima E, et al. The ratio of the neutrophil leucocytes to the lymphocytes predicts the outcome after cardiac resynchronization therapy. Europace. 2016 May;18(5):747-54. DOI: 10.1093/europace/euv100 Search in Google Scholar

44 Martens P, Verbrugge F, Nijst P, Dupont M, Tang WHW, Mullens W. Impact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy. Am J Cardiol. 2017 Jan;119(1):65-70. DOI: 10.1016/j.amjcard.2016.09.017 Search in Google Scholar

45 Venkateswaran RV, Freeman C, Chatterjee N, Kandala J, Orencole M, Vegh EM, et al. Anemia and its association with clinical outcome in heart failure patients undergoing cardiac resynchronization therapy. J Interv Card Electrophysiol. 2015 Dec 1;44(3):297-304. DOI: 10.1007/s10840-015-0062-9 Search in Google Scholar

46 Boros AM, Perge P, Jenei Z, Karády J, Zima E, Molnár L, et al. Measurement of the Red Blood Cell Distribution Width Improves the Risk Prediction in Cardiac Resynchronization Therapy. Dis Markers. 2016;2016:7304538. DOI: 10.1155/2016/7304538 Search in Google Scholar

47 Perge P, Boros AM, Zima E, Gellér L, Merkely B, Széplaki G. Hyperuricemia predicts adverse clinical outcomes after cardiac resynchronization therapy. Scand Cardiovasc J. 2018 Sep 3;52(5):250-5. DOI: 10.1080/14017431.2018.1499954 Search in Google Scholar

48 Rinkuniene D, Bucyte S, Ceseviciute K, Abramavicius S, Baronaite-Dudoniene K, Laukaitiene J, et al. Predictors of positive response to cardiac resynchronization therapy. BMC Cardiovasc Disord. 2014 Apr 29;14(1):55. DOI: 10.1186/1471-2261-14-55 Search in Google Scholar

49 Chatterjee NA, Singh JP, Szymonifka J, Deaño RC, Thai W ee, Wai B, et al. Incremental Value of Cystatin C Over Conventional Renal Metrics for Predicting Clinical Response and Outcomes in Cardiac Resynchronization Therapy: The BIOCRT Study. Int J Cardiol. 2016 Feb 15;205:43-9. DOI: 10.1016/j.ijcard.2015.12.002 Search in Google Scholar

50 Michelucci A, D’Elios MM, Sticchi E, Pieragnoli P, Ricciardi G, Fatini C, et al. Autoantibodies against β1-Adrenergic Receptors: Response to Cardiac Resynchronization Therapy and Renal Function: ANTI-β1-ADRENERGIC RECEPTOR AUTOANTIBODIES AND CRT. Pacing Clin Electrophysiol. 2016 Jan;39(1):65-72. DOI: 10.1111/pace.12757 Search in Google Scholar

51 Moscoso I, Cebro-Márquez M, Martínez-Gómez Á, Abou-Jokh C, Martínez-Monzonís MA, Martínez-Sande JL, et al. Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy. Cells. 2022 Jan 13;11(2):271. DOI: 10.3390/cells11020271 Search in Google Scholar

52 Melman YF, Shah R, Danielson K, Xiao J, Simonson B, Barth A, et al. Circulating MicroRNA-30d is Associated with Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study. Circulation. 2015 Jun 23;131(25):2202-16. DOI: 10.1161/CIRCULATIONAHA.114.013220 Search in Google Scholar

53 Sardu C, Santulli G, Savarese G, Trotta MC, Sacra C, Santamaria M, et al. Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p. Int J Mol Sci. 2023 Jan 12;24(2):1510. DOI: 10.3390/ijms24021510 Search in Google Scholar

54 Yang S, Hu Y, Zhao J, Jing R, Wang J, Gu M, et al. Comprehensive plasma metabolites profiling reveals phosphatidylcholine species as potential predictors for cardiac resynchronization therapy response. ESC Heart Fail. 2021;8(1):280-90. DOI: 10.1002/ehf2.13037 Search in Google Scholar

55 Nemutlu E, Zhang S, Xu YZ, Terzic A, Zhong L, Dzeja PD, et al. Cardiac resynchronization therapy induces adaptive metabolic transitions in the metabolomic profile of heart failure. J Card Fail. 2015 Jun;21(6):460-9. DOI: 10.1016/j.cardfail.2015.04.005 Search in Google Scholar

56 Padeletti L, Modesti PA, Cartei S, Checchi L, Ricciardi G, Pieragnolia P, et al. Metabolomic does not predict response to cardiac resynchronization therapy in patients with heart failure. J Cardiovasc Med Hagerstown Md. 2014 Apr;15(4):295-300. DOI: 10.2459/JCM.0000000000000028 Search in Google Scholar

57 Howell SJ, Stivland T, Stein K, Ellenbogen KA, Tereshchenko LG. Using Machine-Learning for Prediction of the Response to Cardiac Resynchronization Therapy: The SMART-AV Study. JACC Clin Electrophysiol. 2021 Dec;7(12):1505-15. DOI: 10.1016/j. jacep.2021.06.009 Search in Google Scholar

58 Haque A, Stubbs D, Hubig NC, Spinale FG, Richardson WJ. Interpretable machine learning predicts cardiac resynchronization therapy responses from personalized biochemical and biomechanical features. BMC Med Inform Decis Mak. 2022 Oct 31;22(1):282. DOI: 10.1186/s12911-022-02015-0 Search in Google Scholar

59 Cikes M, Sanchez-Martinez S, Claggett B, Duchateau N, Piella G, Butakoff C, et al. Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy. Eur J Heart Fail. 2019 Jan;21(1):74-85. DOI: 10.1002/ejhf.1333 Search in Google Scholar

60 Schmitz B, De Maria R, Gatsios D, Chrysanthakopoulou T, Landolina M, Gasparini M, et al. Identification of genetic markers for treatment success in heart failure patients: insight from cardiac resynchronization therapy. Circ Cardiovasc Genet. 2014 Dec;7(6):760-70. DOI: 10.1161/CIRCGENETICS.113.000384 Search in Google Scholar